Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin

Aramă, Victoria; Munteanu, Daniéla; Streinu-Cercel, Adrian; Ion, Daniela Adriana; Mihăilescu, Raluca; Tilişcan, Cătălin; Tudor, Ana Maria; Aramă, Sorin Ștefan

doi:10.1007/s40618-014-0057-x

Cited by 8 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, a mixed phenotype of HIV-positive patients comprising illicit drug and alcohol use, and anti-retroviral treatment-experienced individuals exhibit lower and upper trunk adipose depots (45) , chronic cannabis smoking is associated with lower abdominal subcutaneous adiposity (46) , cigarette smoking is associated with higher visceral adiposity (47) , while cathinone, the active compound in khat, induces lipolysis in vivo and inhibit free fatty release in isolated adipocytes (48) . Although NRTIs induce increased development of lipodystrophic syndromes in HIV patients (49, 50) , none of our patients exhibited features of lipodystrophy. Therefore, serum adiponectin is a useful surrogate indicator of altered visceral and subcutaneous adiposity in IDUs on anti-retroviral treatment.…”

Section: Discussionmentioning

confidence: 50%

“…In addition, the positive associations of waist perimeter and adiponectin, are partly, similar to previous studies showing increased fatty liver in individuals with higher waist girth previously observed among HCV infected non-alcoholic patients (53) . Abnormal central fat accumulation is a manifestation of HIV-associated lypodystrophy in patients on anti-retroviral treatment (49, 50) . However, central and visceral adiposity in HIV and HCV co-infected treatment-naive and HCV mono-infected IDUs indicates alterations in lipid metabolism.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users

Ndombi¹,

Budambula²,

Webale³

et al. 2015

Endocrine Connections

View full text Add to dashboard Cite

Adiponectin is an important marker of anthropometric profiles of adipose tissue. However, association of adiponectin and adiposity in HIV mono- and co-infected and hepatitis (HCV) injection drug users (IDUs) has not been elucidated. Therefore, the relationship of total adiponectin levels with anthropometric indices of adiposity was examined in HIV mono-infected (anti-retroviral treatment, ART-naive, n=16 and -experienced, n=34); HCV mono-infected, n=36; HIV and HCV co-infected (ART-naive, n=5 and -experienced, n=13); uninfected, n=19 IDUs; and healthy controls, n=16 from coastal Kenya. Anthropometric indices of adiposity were recorded and total circulating adiponectin levels were measured in serum samples using enzyme-linked immunosorbent assay. Adiponectin levels differed significantly amongst the study groups (P<0.0001). Post-hoc analyses revealed decreased levels in HIV mono-infected ART-naive IDUs in comparison to uninfected IDUs (P<0.05) and healthy controls (P<0.05). However, adiponectin levels were elevated in HCV mono-infected IDUs relative to HIV mono-infected ART-naive (P<0.001) and -experienced (P<0.001) as well as HIV and HCV co-infected ART-naive (P<0.05) IDUs. Furthermore, adiponectin correlated with weight (ρ=0.687; P=0.003) and BMI (ρ=0.598; P=0.014) in HIV mono-infected ART-naive IDUs; waist circumference (ρ=−0.626; P<0.0001), hip (ρ=−0.561; P=0.001) circumference, and bust-to-waist ratio (ρ=0.561; P=0.001) in HIV mono-infected ART-experienced IDUs; waist girth (ρ=0.375; P=0.024) in HCV mono-infected IDUs; and waist-to-hip ratio (ρ=−0.872; P=0.048) in HIV and HCV co-infected ART-naive IDUs. Altogether, these results suggest suppression of adiponectin production in treatment-naive HIV mono-infected IDUs and that circulating adiponectin is a useful surrogate marker of altered adiposity in treatment-naive and -experienced HIV and HCV mono- and co-infected IDUs.

show abstract

Section: Discussionmentioning

confidence: 50%

Section: Discussionmentioning

confidence: 99%

Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users

Ndombi¹,

Budambula²,

Webale³

et al. 2015

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…While higher circulating levels of resistin have been implicated in the development of IR 29 and diabetes, 30 its role in HIVLD is inconclusive. Some cross-sectional studies have reported an increase in circulating resistin levels in HIVLD patients, 31 while other studies failed to find an association 32 or even reported a reduction in resistin levels. 33 We observed a significant reduction in the amount of resistin secreted by the adipocyte with all PIs including ATV although the ATV effect was comparatively less than those of other PIs.…”

Section: Discussionmentioning

confidence: 99%

Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistancein vitro

Pushpakom

Adaikalakoteswari

Owen

et al. 2018

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Background:Antiretroviral therapy in HIV-positive patients leads to insulin resistance which is central to the pathogenesis of various metabolic abnormalities and cardiovascular disease seen in this patient group. We have investigated the dose–response relationship of telmisartan, an antihypertensive, on adipocytes in vitro in order to determine whether it may have metabolic beneficial effects.Methods:Using in vitro chronic toxicity models (3T3-F442A murine and primary human adipocytes), we evaluated the effects of different concentrations of telmisartan on adipocyte differentiation and adipogenic gene expression using lipid accumulation assays and real-time polymerase chain reaction, respectively. Adipokine secretion and expression of insulin signalling mediators were evaluated using enzyme-linked immunosorbent assays.Results:Telmisartan partially reversed the deleterious effects of antiretrovirals on adipocyte lipid accumulation, expression of adipogenic regulators (peroxisome proliferator receptor-gamma and lipin 1), adipokine secretion and expression of the insulin signalling mediator pAktSer473. The metabolic effects of telmisartan followed a non-monotonic response with the maximal effect observed at 5 µM in the primary human adipocyte model.Conclusion:Telmisartan has beneficial metabolic effects in adipocytes in vitro, but its potential to reduce antiretroviral-induced cardiometabolic disease in HIV-infected individuals needs to be evaluated in a well-designed adequately powered clinical trial.

show abstract

“…In another study, greater plasma resistin levels were observed in HIV patients compared with uninfected controls [42]. However, other workers have found no association between serum resistin and fat redistribution, and metabolic profile in HIV-infected patients [43,44]. The physiological role of resistin, therefore, is not fully understood and needs further studies.…”

Section: Discussionmentioning

confidence: 94%

Effects of rilpivirine, 17β-estradiol and β-naphthoflavone on the inflammatory status of release of adipocytokines in 3T3-L1 adipocytes in vitro

et al. 2019

View full text Add to dashboard Cite

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor, recently developed as a drug of choice for initial anti-retroviral (ARV) treatment of HIV-1 infection, whereas estradiol is a major component of hormonal contraceptives. Both drugs have effects on lipid metabolism, impairment of adipocyte differentiation and alteration of adipose tissue distribution and function. This study investigated the effects of different concentrations of either rilpivirine or estradiol either alone or in combination on adipocyte differentiation and adipocytokines status in vitro in the absence and presence of β-naphthoflavone, (BNF),a potent agonist of the aryl hydrocarbon receptor. 3T3-L1 human pre-adipocytes were cultured and differentiated with different concentrations of treatment drugs. After 10 days of differentiation procedure, cells were examined for their morphology and viability. Glycerol,adiponectin, leptin, resistin and interleukin-8 (IL-8) were quantified using commercially available kits. The results show that either rilpivirine or estradiol individually or during their combination can evoke significant increases in glycerol release and a concomitant significant decrease of adiponectin from adipocytes. These effects were dose-dependent. The effects of combined treatments were much larger than individual concentration for each drug. Both drugs had little of no effect on leptin levels, except for a small decrease with 10 µM rilpivirine alone or when combined with estradiol. In addition, both drugs evoked small increases in the release of resistin and interleukin-8 with significant values at higher doses compared to untreated adipocytes.When adipocytes were pretreated with BNF, either rilpivirine or, estradiol or when combined evoked a much larger release in glycerol and a much larger decrease in adiponectin compared to the absence of BNF. In contrast, BNF pretreatment had little of no effect on either leptin, resistin or IL-8 metabolism compared to the results obtained in the presence of either rilpivirine or estradiol alone or in combination.These results show that rilpivirine and estradiol either alone or when combined or pretreated with BNF can evoke marked effects on glycerol and cytokines levels from adipocytes. However, their mechanism (s) in inducing adipogenesis warrants further investigation of different transcription factors at gene expression levels.

show abstract

Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin

Cited by 8 publications

References 18 publications

Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users

Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users

Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistancein vitro

Effects of rilpivirine, 17β-estradiol and β-naphthoflavone on the inflammatory status of release of adipocytokines in 3T3-L1 adipocytes in vitro

Contact Info

Product

Resources

About